Back to search

Article

The intricate mechanism through which UMODL1 accelerating tumor proliferation of Her-2 positive breast cancer as well as trastuzumab resistance

2024-06-10

Abstract excerpt

<title>Abstract</title> <p>Abstr act： Human epidermal growth factor receptor 2 positive breast cancer is characterized by the overexpression of the Her-2 receptor, rapid tumor growth, strong invasion ability, and high resistance to chemotherapy. Targeted drug therapies for this subtype include trastuzumab and pertuzumab; however, some patients still show resistance to these treatments. The Uromodulin-1-like (UMOD...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
b2245364-4338-5572-83bd-eba690454c1e
DOI
10.21203/rs.3.rs-4481875/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
The intricate mechanism through which UMODL1 accelerating tumor proliferation of Her-2 positive breast cancer as well as trastuzumab resistanceDOI 10.21203/rs.3.rs-4481875/v1
Neuromedin U: a candidate biomarker and therapeutic target to predict and overcome resistance to HER-tyrosine kinase inhibitors.Semantic proximity
RRM2 as a Key Biomarker and Therapeutic Target in Letrozole-Resistant ER+ Breast Cancer: Insights from Bioinformatics and Molecular DockingSemantic proximity
UGT1A7 altered HER2-positive breast cancer response to trastuzumab by affecting epithelial-to-mesenchymal transition: A potential biomarker to identify patients resistant to trastuzumab treatment.Semantic proximity
VE-822 upregulates the deubiquitinase OTUD1 to stabilize FHL1 to inhibit the progression of lung adenocarcinomaSemantic proximity
ELOVL2: a novel tumor suppressor attenuating tamoxifen resistance in breast cancerSemantic proximity
VE-822 upregulates the deubiquitinase OTUD1 to stabilize FHL1 to inhibit the progression of lung adenocarcinomaSemantic proximity
CHMFL-26 is a highly potent irreversible HER2 inhibitor for use in the treatment of HER2-positive and HER2-mutant cancers.Semantic proximity
Mechanism of action and resistance to Trastuzumab Deruxtecan in patients with metastatic breast cancer: the DAISY trialSemantic proximity
HER2 Expression Associated with Clinical Characteristics and Prognosis of Urothelial Carcinoma in a Chinese PopulationSemantic proximity
Durable Response to Trastuzumab Deruxtecan in a Patient with Urothelial Cancer and ERBB2 Mutation: A Case ReportSemantic proximity
HER2-Driven Breast Tumorigenesis Relies upon Interactions of the Estrogen Receptor with Coactivator MED1.Semantic proximity
FOXO1 Suppression is a Determinant of Acquired Lapatinib-Resistance in HER2-Positive Gastric Cancer Cells Through MET UpregulationSemantic proximity
Select a neighboring publication to make it the new centre.